Hangzhou Sumgen Biotech Co., Ltd. — Biomedical Watch V2

Traitements3programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
SG301 SC InjectionThis is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE).	Lupus	Phase 2	À vérifier	China	À vérifier
SG301 SC InjectionThis is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE).	Lupus	Phase 1	À vérifier	China	À vérifier
SG301 SC InjectionThis is a randomized, double-blind, placebo-controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single dose in healthy volunteers and multiple doses of SG301 SC injection in participants with systemic lupus erythematosus (SLE).	Lupus	Phase 2	À vérifier	China	À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
SG301 SC Injection	Lupus	Phase 2	NCT07447986	To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus	RECRUITING
SG301 SC Injection	Lupus	Phase 1	NCT06144710	SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.